Stock Market Impact: Alnylam shares rose 2.5% in after‑hours trading following the announcement.
Listed Companies and Sectors: Alnylam Pharmaceuticals Inc entered a strategic collaboration with Inceptive Nucleics Inc to combine RNAi technology with generative AI, targeting the biotechnology and AI sectors.
Investment Flows: The agreement provides an upfront payment of $30 million (cash and equity) and is valued at up to $2 billion, with additional milestone payments linked to pre‑clinical, regulatory and commercial achievements.
Interest Rates, Inflation, and Liquidity: No related information disclosed.
Fiscal or Monetary Policy: No related information disclosed.
